Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Haden

Internal Medicine Virginia Beach, VA Medical Doctor

NPI 1316989718 CMS profile 241084

5505 Indian River Rd, Suite 101, Virginia Beach, VA 23464

Open in the dashboard

General payments

$7,570

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Haden of Virginia Beach, VA is reported in the CMS Open Payments database as having received $7,570 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $895 35
2024 General $1,138 36
2023 General $750 39
2022 General $1,156 37
2021 General $1,150 63
2020 General $1,395 79
2019 General $1,087 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Haden
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Haden were reported at $895. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Haden Internal Medicine median Middle half National median
2019 $1,087 $159 $48–$570 $163
2020 $1,395 $119 $33–$402 $114
2021 $1,150 $135 $37–$521 $132
2022 $1,156 $141 $42–$496 $149
2023 $750 $149 $45–$519 $160
2024 $1,138 $154 $47–$537 $164
2025 $895 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,697 74 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,504 79 payments
  3. AstraZeneca Pharmaceuticals LP $1,440 65 payments
  4. Lilly USA, LLC $922 33 payments
  5. GlaxoSmithKline, LLC. $549 26 payments
  6. Pfizer Inc. $476 22 payments
  7. Gilead Sciences, Inc. $147 8 payments
  8. Janssen Pharmaceuticals, Inc $107 6 payments
  9. Sanofi-Aventis U.S. LLC $98 5 payments
  10. Biohaven Pharmaceuticals, Inc. $81 4 payments
  11. Other $549 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,438 347 payments
  2. Education $131 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,066 58 payments
  2. FARXIGA $753 33 payments
  3. JARDIANCE Diabetes $753 45 payments
  4. RYBELSUS $720 43 payments
  5. JARDIANCE Diabetes $492 21 payments
  6. MOUNJARO $441 12 payments
  7. Wegovy $431 7 payments
  8. JARDIANCE Diabetes $344 14 payments
  9. BREZTRI $318 17 payments
  10. TRELEGY ELLIPTA $308 13 payments
  11. Other $4,004 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

5,921

Median for Internal Medicine: 777

Drug cost

$665,587

Median for Internal Medicine: $73,373

Branded share of claims

20.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 104 $116,644
Mounjaro Tirzepatide Brand 75 $99,798
Trulicity Dulaglutide Brand 53 $78,619
Rybelsus Semaglutide Brand 31 $58,169
Xarelto Rivaroxaban Brand 41 $46,806
Eliquis Apixaban Brand 51 $43,038
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $34,773
Imitrex Sumatriptan Succinate Brand 12 $30,193
Spiriva Respimat Tiotropium Bromide Brand 33 $21,480
Januvia Sitagliptin Phosphate Brand 12 $20,190

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$94,540

Of which drugs: $7,373

Medicare patients

263

Average age 74

Services billed

1,851

117 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 43%
Arthritis 42%
Ischemic heart disease 17%
Cancer 17%
Chronic kidney disease 16%
Atrial fibrillation 14%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 60 60 $4,909

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $238
  • Lilly USA, LLC $58
$297 104 —
Wegovy
  • Novo Nordisk Inc $249
$249 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $164
$164 — —
MOUNJARO
  • Lilly USA, LLC $154
$154 75 —
Ozempic
  • Novo Nordisk Inc $92
$92 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record